announced today the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101. AB-101 is a non-genetically modified, cord blood-derived ...

STOCKHOLM, April 26, 2018 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today informs that data from the initial phase IIa study of MIV-711, which demonstrated disease-modifying activity in ...